Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide epoxy ketone compound

A compound and solvate technology, applied in the direction of peptides, drug combinations, peptide/protein components, etc., can solve problems such as inability to inhibit T-L activity, PGPH activity, etc.

Active Publication Date: 2014-02-12
圣特莱国际公司
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these polypeptide epoxy ketones only inhibit the CT-L activity of 20S proteasome, but cannot inhibit the T-L activity and / or PGPH activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide epoxy ketone compound
  • Polypeptide epoxy ketone compound
  • Polypeptide epoxy ketone compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0210] Example 1: Determination of Inhibition of 20S Proteasome CT-L, T-L, and PGPH Activities in Vitro.

[0211]The purified human 20S proteasome was used for in vitro determination of CT-L, T-L and PGPH activities. The concentrations of 20S proteasome were 2, 4 and 8 nmol / L, respectively, and succinyl-Leu-Leu-Val-Tyr-AMC ( 10 μmol / L), Z-leu-Leu-Glu-AMC (10 μmol / L) and Boc-Leu-Arg-Arg-AMC (50 μmol / L) were used as substrates, and the reaction contained 0.5mM ethylenediaminetetraacetic acid, 0.001% sodium dodecyl sulfate (SDS) and 0.05% NP-40 in 20mM triisopropylethanesulfonyl buffer solution (pH8.0). Stock solutions of proteasome inhibitors were prepared in dimethylsulfoxide (DMSO), the final concentration of DMSO in the test mixture was 1%. The reaction was carried out at a temperature of 27°C. Proteasome activity was determined by detecting the cleaved 7-amino-4-methylcoumarin fluorophore with a fluorophotometer. IC 50 (Half inhibitory concentration) values ​​were determ...

Embodiment 2

[0212] Example 2: Determination of the inhibitory effect on CT-L, T-L and PGPH activities of 20S proteasome in blood.

[0213] Take 800 microliters of fresh whole blood samples from CD-1 mice by cardiac puncture into test tubes containing sodium heparin, centrifuge at 150xg for 5 minutes at 4°C, and wash the centrifuged precipitate with ice-cold phosphate-buffered saline three times. Each time the pellet was redissolved in 1 mL of cold phosphate-buffered saline and centrifuged at 6000 x g for 10 min at 4 °C. After the last wash, 200 μL of dissociation solution (phosphate-buffered saline containing 5 mM EDTA, pH 8.0) was added, kept for 1 hour, and the cells were dissociated, and then centrifuged at 6000×g for 10 minutes at 4°C. The protein concentration in the above-mentioned blood lysate was determined by the bicincholic acid method (BCA). Add about 100 μ g protein to HEPES buffer solution (pH7.5); Add 0.2, 1 or 5 μ M of the compound of the present invention to the above mi...

Embodiment 3

[0214] Example 3: Determination of Inhibition of CT-L, T-L and PGPH Activities of 20S Proteasome in Vivo.

[0215] In vivo proteasome activity assays were performed in BALB / c nude mice. Take the polypeptide epoxy ketone compound described in the present invention as the test article and administer it to mice (every group of 5-6 mice) by intravenous injection in a tolerable dose, and the test article is prepared in a mixture containing 10-20 %(w / v) hydroxypropyl-B-cyclodextrin, 2.5% DMSO and 10mM sodium citrate in the vehicle (pH3.0-3.5). One hour after the injection, a whole blood sample was collected by cardiac puncture into a test tube containing sodium heparin and centrifuged at 150xg for 5 minutes at 4°C. The centrifuged pellet was washed three times with ice-cold phosphate-buffered saline. Each time the pellet was redissolved in 1 mL of cold phosphate-buffered saline and centrifuged at 6000 x g for 10 min at 4 °C. After the last wash, 200 μL of dissociation solution (p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an inhibitor whose new compound and pharmaceutical composition can be used as proteasome. The compound of the invention can prevent three activities CT-L, T-L and PGPH of the proteasome, and can be used for treating various diseases related to proteasome.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 61 / 675,827 filed on July 26, 2012, and Chinese Application No. 201210352544.5 filed on September 20, 2012. Both applications are hereby incorporated by reference in their entirety. field of invention [0003] The present invention relates to compounds of polypeptide epoxy ketone structure. These compounds can be used to inhibit the activity of the proteasome. technical background [0004] The proteasome is a protease complex with multiple catalytic functions, which plays a key role in the degradation of intracellular proteins. It is generally believed that proteasome exists in the body as 26S proteasome, its molecular weight is about 2000kDa, and it contains a 20S core particle (20S proteasome) and two 19S regulatory particles. The 20S core particle is a hollow structure, which encloses the active site of degrading protein in the cavity. Each end o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06A61K38/08A61P35/00A61P25/28A61P9/10A61P29/00A61P37/02A61P31/18A61P37/06A61P31/00A61P33/00A61P27/02A61P11/00A61P21/00A61P19/00
Inventor 范晓青岑坚
Owner 圣特莱国际公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com